Price Alert

Stoke Therapeutics Inc. (STOK)

NASDAQ: STOK · Real-Time Price · USD

25.56

0.74 (2.98%)

At close: Oct 03, 2025, 3:59 PM

25.95

1.53%

After-hours: Oct 03, 2025, 07:40 PM EDT

2.98% (1D)

Bid	24
Market Cap	1.4B
Revenue (ttm)	199.89M
Net Income (ttm)	52.48M
EPS (ttm)	0.87
PE Ratio (ttm)	29.38
Forward PE	-8.8
Analyst	Buy
Dividends	n/a

Ask	25.95
Volume	724,339
Avg. Volume (20D)	951,450.2
Open	25.00
Previous Close	24.82
Day's Range	24.68 - 25.61
52-Week Range	5.35 - 25.61
Beta	1.24
Ex-Dividend Date	n/a

About STOK

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol STOK

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for STOK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Stoke Therapeutics Inc. is scheduled to release its earnings on Nov 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+24.98%

Stoke Therapeutics shares are trading higher after... Unlock content with Pro Subscription

2 months ago

+7.04%

Stoke Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a price target of $30.

News

2 weeks ago · businesswire.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

1 month ago · businesswire.com

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...

1 month ago · zacks.com

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago.

1 month ago · businesswire.com

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.